New-onset allergic diseases after SARS-CoV-2 infection: mechanistic hypotheses and emerging strategies for risk stratification
-
By
-
Encheng Li
-
Manying Shi
-
Shixiang Huang
-
June 19, 2026
-
Clinical Scorecard: Emergence of Allergic Conditions Following SARS-CoV-2 Infection: Proposed Mechanisms and New Approaches for Risk Assessment
At a Glance
| Category | Detail |
|---|
| Condition | Allergic Diseases |
| Key Mechanisms | Epithelial injury, immune reprogramming, and mast cell activation linked to SARS-CoV-2 infection. |
| Target Population | Individuals with a history of SARS-CoV-2 infection. |
| Care Setting | Post-infection clinical assessment and management. |
Key Highlights
- SARS-CoV-2 infection associated with increased risk of asthma (HR 2.25) and allergic rhinitis (HR 1.23).
- Elevated risks persist beyond six months post-infection.
- Mechanisms include IL-33 release, TSLP and IL-25 production, and mast cell activation.
- Risk stratification may identify individuals needing targeted surveillance.
- Proposed interventions include low-dose interleukin-2 and mast cell stabilizers.
Guideline-Based Recommendations
Diagnosis
- Assess allergic disease history and symptoms post-SARS-CoV-2 infection.
Management
- Consider mechanistically informed interventions for at-risk individuals.
Monitoring & Follow-up
- Monitor circulating biomarkers such as immunoglobulin E and eosinophil counts.
Risks
- Increased susceptibility to allergic diseases following SARS-CoV-2 infection.
Patient & Prescribing Data
Individuals recovering from SARS-CoV-2 infection.
Potential use of alarmin-targeted biologics and mast cell stabilizers.
Clinical Best Practices
- Evaluate immune status and allergic sensitization in post-COVID patients.
- Implement targeted surveillance for allergic disease in high-risk populations.
- Utilize a multidisciplinary approach to manage post-infectious allergic conditions.
Related Resources & Content
